What Is a KOL Platform, and What Isn’t?

Defining the category for pharmaceutical, biotechnology, medical device, and nutrition companies

By the SteepRock Client Services Team | A collaboration drawing on 25 years of KOL engagement practice

July 2026

Which “KOL platform” are you evaluating for life sciences?

Search the term today and you will mostly find influencer marketing software: tools for creators, sponsored posts, and campaign payments. That is a legitimate category. It just isn’t yours. So before you shortlist a single vendor, agree on the definition:

A KOL platform is technology that helps life sciences organizations, including pharmaceutical, biotechnology, medical device, and nutrition companies, identify, understand, and compliantly engage the scientific experts who shape medical practice and scientific communication.

That definition is not spin; it is history. “Opinion leader” comes from 1940s communications research, and the concept entered medicine in the 1950s through the landmark Medical Innovation study of how physicians adopt new therapies.1 The pharmaceutical industry has organized expert engagement around it ever since.2 The marketing world borrowed the vocabulary half a century later. This article gives it back its meaning.

Diagram contrasting influencer marketing platforms with scientific KOL platforms covering traditional KOLs, digital opinion leaders, and community voices.

One name, two categories

Marketing KOL platforms index social creators and measure success in reach and conversion. Scientific KOL platforms serve medical affairs and commercial teams. They map the experts in a therapeutic area through publications, trials, guidelines, and congress and digital activity, and they operate under rules that consumer tools were never built for: transparency reporting,3 fair market value, and the separation of promotional and non-promotional engagement.

Pick from the wrong category and the cost is immediate. The tool cannot say who leads the pivotal trials in your indication, which experts are shaping the treatment paradigm, or whether your engagement history with a clinician across every function is compliant. That is not a feature gap. It is the wrong model of influence entirely.

Engagement is the goal

Identification is not the destination. Profiles, rankings, and network maps are the means; engagement is the goal, because engagement is how an organization earns its place in scientific communication. Scientific opinion is formed in conversation: at advisory boards, in congress hallways, in MSL exchanges, and increasingly in digital threads. An organization that only observes that conversation has intelligence. One that engages in it compliantly, credibly, and consistently helps advance it. Evidence gaps get surfaced, education reaches the clinicians who change care, and the science around a therapy is built on genuine exchange rather than promotion.

Commercial teams engage the same experts within promotional rules, which is exactly why the platform must keep the two motions coordinated yet distinct. A true KOL platform is engagement infrastructure, not a directory. Identification, influence mapping, insight generation, and cross-functional coordination, increasingly with AI embedded in the workflow, all exist to shorten the path from “we know who matters” to “we are in a meaningful, compliant dialogue with them.”

Three kinds of experts, one system of influence

Medical influence now operates in three layers, and the strategic value of engagement is different in each. Treating them as one undifferentiated “KOL list,” or covering only one layer, forfeits most of what engagement can achieve.

Traditional KOLs are the evidence layer. Principal investigators, guideline authors, and society leaders do not merely comment on the evidence; they generate it. Engagement here means a seat in evidence generation itself: trial leadership, investigator-initiated studies, and advisory relationships that surface data gaps while they can still be addressed. Diffusion research has shown since the 1950s that physicians adopt new therapies through trusted peers, not mass communication.1 These are the peers the peers trust.
DOLs are the interpretation layer. Data readouts are now analyzed in public and in near-real time; a credentialed expert’s congress thread reaches practicing clinicians in hours, not publication cycles.4 Whether the first widely read interpretation of your data is accurate, contextualized, and scientifically grounded depends on whether you have genuine relationships in that channel before the readout, not after. As we have argued in our KOL vs. DOL analysis,6 the two roles increasingly overlap in the same individuals, which is precisely why they must be understood and engaged as distinct modes of influence. Peer-reviewed work now formally separates DOLs from social media influencers on the dimension that matters: credentials.5
Community and emerging voices are the adoption layer. This is the layer with the strongest outcome evidence: a Cochrane review of randomized trials found that local opinion leaders measurably improve clinicians’ compliance with evidence-based practice.7 Community clinicians determine real-world uptake; advocacy leaders shape access, policy, and trial recruitment; and today’s rising investigators are the next decade’s guideline authors. Those relationships are best begun before everyone else wants them.

These are not three audiences. They are one system: evidence is generated at the top, interpreted in digital channels, and adopted in the community. An engagement strategy that skips a layer breaks the chain from evidence to practice and cedes that layer to a competitor who didn’t.

The SteepRock standard

SteepRock has built KOL and expert-engagement technology exclusively for life sciences since 2001, when it pioneered the first Opinion Leader Management System (OLMS), before “KOL platform” was a search term. More than 400 pharmaceutical, biotechnology, medical device, and nutrition companies have relied on our platforms:

OLA (Opinion Leader Analytics): Continuously analyzes publications, clinical trials, congress participation, claims data, referral networks, Open Payments records, and digital media to identify and measure scientific influence in real time.
OLMS (Opinion Leader Management System): Manages the complete lifecycle of compliant expert engagement, from planning and interactions to advisory boards, insights, and relationship history.
Embedded Intelligence: AI-native capabilities that transform internal and external data into conversational insights, recommendations, summaries, and live analytics.

All are built to see the three layers of influence in one system. Nine of the ten largest pharmaceutical companies have engaged SteepRock at one time or another, and it is not uncommon for clients to work with us for decades. In a category defined by long-term, compliant expert relationships, that longevity is the point.

Everything else is influencer marketing software. Both categories can be excellent at what they do; they just shouldn’t share a name without a definition. So, once more: which “KOL platform” are you evaluating?

The overlap matters more than the distinction

Here is the part strategy teams most often get wrong: KOL and DOL are not mutually exclusive categories. They are different modes of influence, and the map of who holds each is constantly shifting. Some of the most influential voices in a therapeutic area are hybrids: guideline authors with large digital followings. Others are pure DOLs with modest publication records but enormous reach among community physicians. And some deeply influential KOLs have no digital footprint at all.

Treating these as one list produces blind spots in both directions: engage only traditional KOLs and you miss day-of-data sentiment; chase follower counts and you miss the experts who will actually write the guidelines.

Medical affairs leaders increasingly describe the answer as an integrated influence map, a single view that combines digital influence signals with traditional KOL identification so that field teams can prioritize experts who carry weight in both worlds [6, 7].

How life sciences teams identify DOLs

Follower counts and raw volume are among the least informative signals available. A network analysis of the ESMO 2018 congress conversation illustrates why: commercial accounts made up under 10% of tweeters yet produced roughly 16% of tweets and drew nearly a quarter of all retweets. Even so, they were far less likely than non-commercial voices to be cited or mentioned by their peers [2]. Volume and even retweets can be inflated by sources that carry little genuine influence among clinicians. Rigorous DOL identification weighs signals like these instead:

Relevance. Does this voice consistently discuss the disease area, mechanism, or treatment landscape in question, or is healthcare a minor part of a general feed?
Engagement quality. Are clinicians and researchers responding, sharing, and debating this person's content, or is engagement primarily from the public?
Network position. Is this voice connected to, cited by, or amplified by other recognized experts?
Velocity and timing. Is this person shaping the conversation at key moments such as data readouts, congress sessions, and label changes, or commenting only after consensus forms?
Trajectory. Rising voices matter as much as established ones. DOL influence changes far faster than KOL standing, and today's active fellow with a sharp tweetorial habit may be tomorrow's hybrid expert.

Because these signals live across platforms and change daily, DOL identification at scale is an analytics problem, not a manual research task.

Why the distinction changes engagement strategy

KOLs and DOLs warrant different engagement models. Traditional KOL engagement runs through advisory boards, investigator relationships, congress meetings, and publication planning. DOL engagement centers on scientific exchange and education, ensuring that accurate, balanced information reaches the digital conversations where sentiment is actually forming. It also carries compliance considerations specific to public digital channels, including privacy and data usage, fair market value, pharmacovigilance obligations when listening to public conversation, and the distinction between passive listening and active engagement. Medical affairs bodies have treated this as a priority as DOL collaboration has matured [5, 6].

The practical implication for medical affairs teams is a single stakeholder view that tracks both modes of influence: who publishes, who presents, who posts, who gets amplified, and how each expert's beliefs about science are evolving across all of those channels at once.

How SteepRock helps

SteepRock approaches this as one problem, not two.

OLA®(Opinion Leader Analytics) is a proprietary advanced search engine within SteepRock's Embedded Intelligence service, spanning scientific, commercial, regulatory, and digital data domains across life sciences. OLA identifies and profiles both KOLs and DOLs in any disease area, analyzing publications, clinical trials, congress activity, claims and referral data, and social and digital media in real time. It surfaces the digital voices traditional KOL lists miss alongside the institutional experts they overlap with.

SteepRock Embedded Intelligence is the unified, agentic intelligence layer that operates natively across those data domains as a single environment. It brings generative AI directly into the workflow, summarizing expert profiles, synthesizing engagement history, drafting insights, and answering natural-language questions across your stakeholder data. For KOL and DOL strategy, that means a team can pose a question no single data source can answer, such as which rising DOLs matter in a therapeutic area and how expert sentiment has shifted since a congress readout, and receive a synthesized, evidence-linked answer drawn from publications, congress activity, and digital conversation at once.

OLMS™ (Opinion Leader Management System) then gives medical affairs and commercial teams one compliant system of record for engaging both KOLs and DOLs, connecting external influence signals with internal engagement history so that the influence map and the engagement plan live in the same place.

See how OLA and Embedded Intelligence map KOL and DOL influence in your disease area

The overlap matters more than the distinction

Here is the part strategy teams most often get wrong: KOL and DOL are not mutually exclusive categories. They are different modes of influence, and the map of who holds each is constantly shifting. Some of the most influential voices in a therapeutic area are hybrids — guideline authors with large digital followings. Others are pure DOLs with modest publication records but enormous reach among community physicians. Some deeply influential KOLs have no digital footprint at all

Treating these as one list produces blind spots in both directions: engage only traditional KOLs and you miss day-of-data sentiment; chase follower counts and you miss the experts who will actually write the guidelines.

Medical affairs leaders increasingly describe the answer as an integrated influence map — one view that combines digital influence signals with traditional KOL identification, so field teams can prioritize experts who carry weight in both worlds [6, 7].

How life sciences teams identify DOLs

Follower counts are the least informative signal available, not least because congress-period conversation attracts noise: one analysis of ESMO congress activity found heterogeneous sources competing for attention in the same hashtags, including substantial commercial and low-quality content [2]. Rigorous DOL identification weighs signals like these instead:

Relevance. Does this voice consistently discuss the disease area, mechanism, or treatment landscape in question — or is healthcare a minor part of a general feed?
Engagement quality. Are clinicians and researchers responding, sharing, and debating this person's content, or is engagement primarily from the public?
Network position. Is this voice connected to, cited by, or amplified by other recognized experts?
Velocity and timing. Is this person shaping the conversation at key moments — data readouts, congress sessions, label changes — or commenting after consensus forms?
Trajectory. Rising voices matter as much as established ones. DOL influence changes far faster than KOL standing, and today's active fellow with a sharp tweetorial habit may be tomorrow's hybrid expert.

Because these signals live across platforms and change daily, DOL identification at scale is an analytics problem, not a manual research task.

Why the distinction changes engagement strategy

KOLs and DOLs warrant different engagement models. Traditional KOL engagement runs through advisory boards, investigator relationships, congress meetings, and publication planning. DOL engagement centers on scientific exchange and education — making sure accurate, balanced information reaches the digital conversations where sentiment is actually forming — and it carries compliance considerations specific to public digital channels, a topic medical affairs bodies have flagged as a priority as DOL collaboration matures [6].

The practical implication for medical affairs teams is a single stakeholder view that tracks both modes of influence: who publishes, who presents, who posts, who gets amplified — and how each expert's beliefs about the science are evolving across all of those channels at once.

How SteepRock helps

SteepRock approaches this as one problem, not two.

OLA™ (Opinion Leader Analytics) is a proprietary advanced search engine within SteepRock's Embedded Intelligence service, spanning scientific, commercial, regulatory, and digital data domains across life sciences. OLA identifies and profiles both KOLs and DOLs in any disease area, analyzing publications, clinical trials, congress activity, claims and referral data, and social and digital media in real time — surfacing the digital voices traditional KOL lists miss alongside the institutional experts they overlap with.

SteepRock Embedded Intelligence is the unified, agentic intelligence layer that operates natively across those data domains as a single environment. It brings generative AI directly into the workflow — summarizing expert profiles, synthesizing engagement history, drafting insights, and answering natural-language questions across your stakeholder data. For KOL/DOL strategy, that means a team can ask questions no single data source can answer — “Who are the rising DOLs in our therapeutic area, and how has expert sentiment shifted since the congress readout?” — and get a synthesized, evidence-linked answer drawn from publications, congress activity, and digital conversation at once.

OLMS™ (Opinion Leader Management System) then gives medical affairs and commercial teams one compliant system of record for engaging both KOLs and DOLs — connecting external influence signals with internal engagement history, so the influence map and the engagement plan live in the same place.

See how OLA and Embedded Intelligence map KOL and DOL influence in your disease area:

Frequently Asked Questions

What is a KOL platform?

Is a KOL platform the same as an influencer marketing platform?

What is a Digital Opinion Leader (DOL)?

References

1. Coleman JS, Katz E, Menzel H. Medical Innovation: A Diffusion Study. Bobbs-Merrill, 1966. The study that brought opinion leader research into medicine.

2. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336(7658):1402–1403. https://pmc.ncbi.nlm.nih.gov/articles/PMC2432185/

3. Centers for Medicare & Medicaid Services. Open Payments (Physician Payments Sunshine Act). https://www.cms.gov/openpayments

4. Medical Affairs Professional Society. Digital Opinion Leaders and HCP Influence Mapping. 2025. https://medicalaffairs.org/dol-hcp-influence/

5. The role of digital opinion leaders in dengue prevention through health promotion and public health collaboration. J Med Internet Res. 2025;27:e70997. Includes a formal comparison of KOLs, DOLs, and social media influencers. https://www.jmir.org/2025/1/e70997

6. SteepRock. KOL vs. DOL: understanding the two modes of medical influence. https://www.steeprockinc.com/kol-vs-dol